News
cridge
Thu, 10/15/2026 – 10:05
On September 18, 2026, the Department of Justice (DOJ) issued two significant updates to the Justice Manual affecting False Claims Act (FCA) enforcement. First, DOJ attorneys are now required to affirmatively assess whether dismissal of a qui tam action serves
In Cude v. Lincoln National Life Insurance Company, No. 8:25-cv-00123-AH-KESx, 2026 WL 3036131 (C.D. Cal. Oct. 9, 2026), District Judge Anne Hwang of the United States District Court for the Central District of California addressed whether a general release
NIH All of Us Research Program Tribal Consultation
On Monday, October 19, 2026, from 12:00 p.m. to 2:00 p.m. Pacific Time, NIH will conduct a Tribal consultation concerning two new initiatives within the All
The Employee Benefits Security Administration (EBSA), a division of the U.S. Department of Labor (DOL), recently issued guidance for employer health plans on compliance with federal mental health and substance use disorder parity laws. However, litigation over the rules remains
A doctor in Victoria has been reprimanded and suspended for six months after he struck a patient in the face, twice, and abused him. The longer story is that the patient ‘was verbally and physically aggressive’ (Medical Board of Australia
This update summarizes the Global Benchmark for Efficient Drug Pricing Model, addresses key considerations for industry, and assesses what may come next.
On September 30, 2026, the Centers for Medicare & Medicaid Services (CMS) released the final rule for the
On October 1, 2026, Sanofi and Regeneron Pharmaceuticals, Inc. (“Regeneron”) announced an expansion of their existing immunology collaboration to develop and commercialize four long-acting antibodies. Sanofi will pay Regeneron $1 billion upfront, with up to an additional $7 billion in
On October 5, 2026, Celltrion USA announced that OMLYCLO® (omalizumab-igec) is commercially available in the United States. OMLYCLO® is the first and only FDA-approved interchangeable biosimilar to Genentech and Novartis’s XOLAIR® (omalizumab).
As we previously reported, the FDA approved the
By Joseph Ciaccio, Partner overseeing the Medical Malpractice and Personal Injury Litigation Departments
Van Duyn Center for Rehabilitation and Nursing in Syracuse, New York, has been under an admissions freeze since January after repeated violations that state regulators called dangerous enough to warrant intervention. The
